We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.8%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$5.06B
AUM Growth
+$476M
Cap. Flow
+$367M
Cap. Flow %
7.25%
Top 10 Hldgs %
27.38%
Holding
165
New
14
Increased
67
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
AGL icon
Agilon Health
AGL
+$245M
2
LENZ
LENZ Therapeutics
LENZ
+$53.5M
3
NEUE
NeueHealth
NEUE
+$40.7M
4
VERV
Verve Therapeutics
VERV
+$40M
5
LFST icon
Lifestance Health
LFST
+$39.6M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$100M
2
AZN icon
AstraZeneca
AZN
+$32.3M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$27.2M
4
INSP icon
Inspire Medical Systems
INSP
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 94.21%
2 Consumer Staples 1.63%
3 Industrials 0.71%
4 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
51
Boston Scientific
BSX
$71.5B
$34.2M 0.68%
800,000
– –
PPD
52
DELISTED
PPD, Inc. Common Stock
PPD
$31.1M 0.61%
675,000
– –
ASND icon
53
Ascendis Pharma A/S
ASND
$16.8B
$30.7M 0.61%
233,500
– –
KYMR icon
54
Kymera Therapeutics
KYMR
$8.94B
$30.4M 0.6%
626,527
+4,750
+0.8% +$206K
IRTC icon
55
iRhythm Holdings
IRTC
$4.2B
$29.7M 0.59%
448,000
+15,504
+4% +$1.23M
CGEM icon
56
Cullinan Oncology
CGEM
$1.14B
$27.7M 0.55%
1,075,912
– –
ADPT icon
57
Adaptive Biotechnologies
ADPT
$3.97B
$26.6M 0.52%
650,000
– –
MIRM icon
58
Mirum Pharmaceuticals
MIRM
$6.14B
$26.3M 0.52%
1,523,723
+20,923
+1% +$375K
LUNG icon
59
Pulmonx
LUNG
$87.6M
$26.1M 0.52%
592,500
– –
ALLK
60
DELISTED
Allakos
ALLK
$26.1M 0.52%
305,706
– –
CERE
61
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$26.1M 0.51%
1,016,945
+11,845
+1% +$170K
MDGL icon
62
Madrigal Pharmaceuticals
MDGL
$11.8B
$25.6M 0.51%
262,500
+4,000
+2% +$474K
SRPT icon
63
Sarepta Therapeutics
SRPT
$1.77B
$25.6M 0.51%
328,750
– –
BOLT icon
64
Bolt Biotherapeutics
BOLT
$7.78M
$25M 0.49%
80,962
+3,000
+4% +$1.22M
EPZM
65
DELISTED
Epizyme, Inc
EPZM
$25M 0.49%
3,011,487
+208,533
+7% +$1.76M
GH icon
66
Guardant Health
GH
$22.6B
$24.8M 0.49%
200,000
– –
ACAD icon
67
Acadia Pharmaceuticals
ACAD
$5.03B
$24.4M 0.48%
1,000,000
-76,200
-7% -$1.72M
CNMD icon
68
CONMED
CNMD
$1.47B
$22.3M 0.44%
162,500
+77,415
+91% +$10.6M
OSH
69
DELISTED
Oak Street Health, Inc.
OSH
$22M 0.43%
375,000
– –
TVTX icon
70
Travere Therapeutics
TVTX
$5.78B
$21.8M 0.43%
1,494,164
+18,600
+1% +$367K
COLL icon
71
Collegium Pharmaceutical
COLL
$956M
$21.7M 0.43%
920,000
– –
BMRN icon
72
BioMarin Pharmaceuticals
BMRN
$12.4B
$21.2M 0.42%
253,500
– –
ABCM
73
DELISTED
Abcam PLC
ABCM
$20.9M 0.41%
1,097,500
+28,264
+3% +$563K
XENT
74
DELISTED
Intersect ENT, Inc
XENT
$20.9M 0.41%
1,220,000
+139,800
+13% +$2.62M
RIGL icon
75
Rigel Pharmaceuticals
RIGL
$750M
$20.6M 0.41%
475,490
+1,290
+0.3% +$48.7K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rock Springs Capital Management held 165 positions worth $5.06B, up 10% from $4.58B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $367M of net new capital in Q2 2021, opening 14 new positions and adding to 67 existing holdings. Its largest new stake was Agilon Health: 279,961 shares worth $284M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $27.2M trimmed.

  • Rock Springs Capital Management's largest Q2 2021 buy was Agilon Health: 279,961 shares worth $284M.
  • Rock Springs Capital Management added most to Eargo, Inc. Common Stock in Q2 2021, an estimated $25.1M increase.
  • Rock Springs Capital Management's biggest Q2 2021 reduction was Atea Pharmaceuticals, cutting an estimated $27.2M.
  • Rock Springs Capital Management fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $100M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $5.06B portfolio in Q2 2021.
  • Rock Springs Capital Management opened 14 new positions and closed 9 in Q2 2021.
  • Rock Springs Capital Management's portfolio value rose 10% quarter-over-quarter to $5.06B.

Based on Rock Springs Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.